Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia

Zhang, Hanrui; Vallim, Thomas Q. de Aguiar; Martel, Catherine

doi:10.1161/atvbaha.116.307808

Cited by 5 publications

(5 citation statements)

References 57 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, LDL management is the primary aim in clinical practice to reduce acute CVDs events. Statins, proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors, apolipoprotein A-I-based therapies, and other lipid-lowering therapies have been demonstrated to reduce CVDs events (Zhang et al, 2016;Pulipati and Davidson, 2020). In our study, both TC and LDL-C were significantly decreased by IF treatment, indicating amelioration of hypercholesterolemia is one of the main contributors in the reduction of atherosclerosis.…”

Section: Discussionmentioning

confidence: 56%

Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

Chen

Yan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Atherosclerosis is a major pathology for cardiovascular diseases (CVDs). Clinically, the intermittent fasting (IF) has been observed to reduce the risk of CVDs. However, the effect of IF on the development of atherosclerosis has not been fully elucidated. Herein, we determined the protection of IF against high-fat diet–induced atherosclerosis in pro-atherogenic low-density lipoprotein receptor deficient (LDLR-/-) mice and the potentially involved mechanisms. The LDLR-/- mice were scheduled intermittent fasting cycles of 3-day HFD feeding ad libitum and 1 day fasting, while the mice in the control group were continuously fed HFD. The treatment was lasted for 7 weeks (∼12 cycles) or 14 weeks (∼24 cycles). Associated with the reduced total HFD intake, IF substantially reduced lesions in the en face aorta and aortic root sinus. It also increased plaque stability by increasing the smooth muscle cell (SMC)/collagen content and fibrotic cap thickness while reducing macrophage accumulation and necrotic core areas. Mechanistically, IF reduced serum total and LDL cholesterol levels by inhibiting cholesterol synthesis in the liver. Meanwhile, HFD-induced hepatic lipid accumulation was attenuated by IF. Interestingly, circulating Ly6Chigh monocytes but not T cells and serum c-c motif chemokine ligand 2 levels were significantly reduced by IF. Functionally, adhesion of monocytes to the aortic endothelium was decreased by IF via inhibiting VCAM-1 and ICAM-1 expression. Taken together, our study indicates that IF reduces atherosclerosis in LDLR-/- mice by reducing monocyte chemoattraction/adhesion and ameliorating hypercholesterolemia and suggests its potential application for atherosclerosis treatment.

show abstract

Section: Discussionmentioning

confidence: 56%

Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

Chen

Yan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Devido a esses e outros estudos, há muitas décadas se conhece o efeito modificador do perfil lipídico exercido pela vitamina B3, o qual promove o aumento de HDL e a diminuição de LDL e TG, assim como sua ação na prevenção de doenças cardiovasculares (D'ANDREA et al, 2019, DUNBAR e GOEL, 2016, ZHANG et al, 2016, KRAMER, 2015, SUPERKO et al, 2017. Os mecanismos de ação ainda não são totalmente estabelecidos, mas sabe-se que a Niacina atua em várias vias metabólicas no organismo (DUNBAR e GOEL, 2016, KRAMER, 2015.…”

Section: Resultsunclassified

“…As DCV representam, atualmente, uma das principais causas de morte no mundo, de forma que a discussão sobre a redução dos fatores de risco e mudança de hábitos de vida se torna essencial. (KRAMER, 2015, ZHANG et al, 2016 As dislipidemias primárias estão associadas, em geral, a mutações ou fatores genéticos, como hipercolesterolemia familiar. Já as secundárias, a maioria dos casos, são consequências de outras doenças ou condições de saúde, como diabetes, hipertireodismo ou maus hábitos de vida.…”

unclassified

Terapia Nutricional Para Pacientes Hospitalizados Com Covid-19

Ferreira¹,

Vieira²,

Santos³

et al. 2021

Nutrição Experimental E Clínica E Sua Ação Transformadora 2

View full text Add to dashboard Cite

show abstract

“…5 PCSK9 is a circulating protein that regulates hepatic and serum low-density lipoprotein (LDL) cholesterol levels. 36, 37 Evolocumab, a human monoclonal antibody that blocks the interaction between PCSK9 and the LDL receptor, was evaluated in the FOURTIER randomized clinical trial.…”

Section: Targeted Therapiesmentioning

confidence: 99%

“…The first targeted CVD therapy that has been developed is a PCSK9 (proprotein convertase subtilisin-kexin type 9) antibody for the treatment of hypercholesterolaemia. 5 Its approval paved the way for the clinical evaluation of an actual anti-inflammatory CVD immunotherapy directed against interleukin-1β (IL-1β) in the CANTOS trial. The disclosure of the primary endpoint led to a lot of excitement about the trial’s results, suggesting an extensive reduction of secondary cardiovascular events.…”

Section: Introductionmentioning

confidence: 99%